Lymphatic Metastasis Predicts Better Response to Nivolumab in Recurrent or Metastatic Gastric Cancer: Insights from Tumor-Draining Lymph Node Immunity and Long-Term Outcomes.

ABSTRACT:

Introduction

Nivolumab has become an essential therapeutic agent for patients with advanced or recurrent gastric cancer. However, the impact of metastatic patterns on its clinical efficacy has not been fully elucidated. This study aimed to clarify the association between distinct metastatic patterns and outcomes of nivolumab monotherapy.

Methods

Ninety-two patients with advanced or recurrent gastric cancer who received nivolumab were retrospectively analyzed. Clinicopathological variables, including performance status, HER2 expression, and predominant metastatic pattern, were correlated with survival outcomes and response rates.

Results

The median observation period was 48.3 months. The median overall (OS) and progression-free (PFS) survival for the entire cohort were

SUBMITTER: Oya S 

PROVIDER: S-EPMC12790426 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature